What is Dulaglutide?
Dulaglutide, marketed as Trulicity, is a long-acting GLP-1 receptor agonist used in type 2 diabetes care. Its research includes blood-sugar control and cardiovascular outcomes.
Biological role or research focus
Incretin signaling in type 2 diabetes care.
Evidence for a prescribed diabetes product is not evidence for an unverified research vial.
Role reference: MedlinePlus · Dulaglutide injection ↗
Names you may encounter
Trulicity
Search terms can include brands, combinations, or historical names. They are not automatic product equivalents.
- Class
- GLP-1 receptor agonist
- Brand
- Trulicity
- Form
- Once-weekly prescription injection
- Half-life
- Approximately 5 days
Source: FDA · Trulicity prescribing information · March 2026 ↗
Quick answers
- Is Dulaglutide FDA approved?
- Yes. Trulicity (BLA 125469, approved September 2014) for type 2 diabetes, including reducing cardiovascular risk. Source ↗
- Is Dulaglutide safe?
- Approved GLP-1 drug for type 2 diabetes; stomach side effects are common, and it carries a boxed warning about thyroid tumors seen in rats. Human safety data: its FDA label lists the known risks. The Risks & interactions section below lists what is known. Read the risks ↓
- Is Dulaglutide banned in sport?
- It is not named on the 2026 World Anti-Doping Agency (WADA) Prohibited List. Athletes should still check with their sport’s anti-doping body. Source ↗
- Has the FDA taken action over Dulaglutide?
- Yes. Our records list 1 FDA action naming it, most recently on November 9, 2026: FDA Drug Safety Communication requiring all GLP-1 receptor agonist labels to add a warning about a potential increased risk of NAION (non-arteritic anterior ischemic optic neuropathy), a rare optic nerve condition that can cause sudden, painless vision loss in one eye, including permanent loss. Source ↗
What does the evidence show?
Evidence map
Every study featured on this page, grouped by what was actually tested. Human studies count most; animal and cell results often do not carry over to people.
| Study | Type | Population / model |
|---|---|---|
| REWIND (2019) | Human randomized trial | 9,901 adults aged 50 or older with type 2 diabetes and cardiovascular disease or risk factors. |
| AWARD-11 (2021) | Human randomized trial | 1,842 adults with type 2 diabetes inadequately controlled with metformin; mean starting HbA1c 8.6%. |
| AWARD-PEDS (2022) | Human randomized trial | 154 participants aged 10 to under 18 with type 2 diabetes and BMI above the 85th percentile. |
Selected published evidence, with the population, findings, and limits kept together. These original summaries draw on publication abstracts; they are not a systematic review.
Human randomized trial · 2019
REWIND
Does treatment reduce cardiovascular events?
- Population / model
- 9,901 adults aged 50 or older with type 2 diabetes and cardiovascular disease or risk factors.
- Study design
- Randomized, double-blind comparison with placebo added to existing care; median follow-up 5.4 years.
- Main finding
- The combined outcome of cardiovascular death, nonfatal heart attack, or nonfatal stroke occurred in 12.0% with dulaglutide and 13.4% with placebo. Hazard ratio: 0.88 (95% confidence interval 0.79–0.99).
- How to read it
- The observed difference was 1.4 percentage points. The hazard ratio describes a 12% relative reduction in the event hazard, not a 12-percentage-point reduction in risk. All-cause mortality was not significantly different.
- Limits & context
- This was a cardiovascular-risk population with diabetes. The results do not establish a longevity benefit in healthy people. Gastrointestinal events were more frequent with dulaglutide.
Human randomized trial · 2021
AWARD-11
How did higher studied doses compare for glucose and weight?
- Population / model
- 1,842 adults with type 2 diabetes inadequately controlled with metformin; mean starting HbA1c 8.6%.
- Study design
- Randomized 52-week trial comparing three dulaglutide dose groups; primary comparison at 36 weeks.
- Main finding
- In the analysis including treatment discontinuation or rescue medication, HbA1c fell 1.77 percentage points in the 4.5-mg group versus 1.54 in the 1.5-mg group. Weight fell 4.6 kg versus 3.0 kg.
- How to read it
- The 4.5-mg group had greater average reductions. The 3.0-mg group did not meet superiority over 1.5 mg for HbA1c in that analysis, although it did in the on-treatment analysis.
- Limits & context
- The comparator was another dulaglutide dose, not placebo or a different medicine. These are trial groups, not personal dosing instructions. Weight results in metformin-treated diabetes cannot simply be transferred to people without diabetes.
Human randomized trial · 2022
AWARD-PEDS
What was found in younger people with type 2 diabetes?
- Population / model
- 154 participants aged 10 to under 18 with type 2 diabetes and BMI above the 85th percentile.
- Study design
- Double-blind, placebo-controlled trial with a 26-week primary comparison, followed by an open-label extension.
- Main finding
- HbA1c rose 0.6 percentage points with placebo and fell 0.6 and 0.9 points in the two dulaglutide groups. HbA1c below 7% was reached by 51% of the pooled dulaglutide groups versus 14% with placebo.
- How to read it
- Glucose control improved, but the groups did not differ in BMI change. A glucose-lowering result and a weight-loss result are different findings.
- Limits & context
- The study does not establish treatment for obesity alone, children under 10, or long-term cardiovascular outcomes in youth.
These trials were sponsored by Eli Lilly. Read the original paper for methods, adverse events, funding, and conflicts of interest. Publisher access may require a subscription.
Registered human trials
74 registered studies name Dulaglutide as an intervention among the 100 most recently updated of 145 search results; 9 are recruiting or under way, 3 have not started recruiting yet, 52 completed and 10 ended early, were withdrawn or have another status. Checked November 16, 2026 on ClinicalTrials.gov.
A registration shows a study was planned; it is not a result. Some studies use the compound only as a comparison or in a combination. All 74 listed studies.
Search additional PubMed records ↗Risks & interactions
Approved GLP-1 drug for type 2 diabetes; stomach side effects are common, and it carries a boxed warning about thyroid tumors seen in rats.
Thyroid C-cell tumors: dulaglutide caused thyroid C-cell tumors in rats, and it is unknown whether it causes them, including medullary thyroid cancer, in humans. Do not use with a personal or family history of medullary thyroid cancer or MEN 2.
Safety comes from FDA-approved labeling (Trulicity) based on large controlled diabetes trials, including a cardiovascular outcomes trial. Whether the thyroid tumors seen in rats apply to humans is not known.
Take extra care with: Blood thinners or bleeding problemsDiabetes or blood-sugar medicinesCancer, now or in the pastKidney problems
From the FDA label lists below. If a condition applies to you, talk to a doctor or pharmacist first. Each tag opens every profile that mentions it.
Who should not use it
- Personal or family history of medullary thyroid carcinoma (MTC)
- Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
- Past serious allergic reaction to dulaglutide or any product component
- Not recommended with severe gastroparesis (label warning)
Interactions
- Insulin or sulfonylureas: higher risk of low blood sugar
- Oral medicines: slowed stomach emptying can delay absorption
- Narrow-margin oral drugs such as warfarin: levels may need closer monitoring
Serious risks
- Acute pancreatitis
- Severe stomach and gut side effects; kidney injury from dehydration
- Worsening diabetic eye disease in people with a history of it
- Gallbladder disease such as gallstones
- Serious allergic reactions, including anaphylaxis and angioedema
- Inhaling stomach contents during anesthesia or deep sedation
Common side effects
- nausea
- diarrhea
- vomiting
- abdominal pain
- decreased appetite
Summarized from the FDA label with AI assistance; not reviewed by a clinician. Not a complete list, and not medical advice: talk to a doctor or pharmacist about your own situation. Checked 2026-10-10. Sources: DailyMed: Trulicity (dulaglutide) prescribing information ↗
Important label warnings
The boxed warning concerns thyroid C-cell tumors in rodents; human relevance is unknown. Personal or family medullary thyroid carcinoma, MEN 2, and serious hypersensitivity are contraindications. Other warnings include pancreatitis, dehydration-related kidney injury, severe gastrointestinal reactions, retinopathy complications, gallbladder disease, and aspiration during anesthesia. Insulin or sulfonylureas can increase hypoglycemia risk. See the complete label.
Source: FDA · Trulicity prescribing information · March 2026 ↗
Patient information
Reported side effects include nausea, diarrhea, heartburn, reduced appetite, and tiredness. Review other medicines, pregnancy or breastfeeding, and planned procedures with the care team. Persistent severe abdominal pain, breathing difficulty, or face/throat swelling require urgent medical attention.
Source: MedlinePlus · Dulaglutide injection ↗
Regulatory status
- U.S. FDA approval
- Approved
Trulicity (BLA 125469, approved September 2014) for type 2 diabetes, including reducing cardiovascular risk. source - FDA compounding (503A bulk list)
- Not on FDA’s compounding lists
Not on FDA's 503A nominated-substance category lists. As a component of an FDA-approved drug it does not need to be on the 503A bulks list to be used in pharmacy compounding (other 503A conditions still apply). source - World Anti-Doping Agency (2026)
- Not on the WADA Prohibited List
Not named and not within a prohibited class on the 2026 List. source
FDA actions
- FDA Drug Safety Communication requiring all GLP-1 receptor agonist labels to add a warning about a potential increased risk of NAION (non-arteritic anterior ischemic optic neuropathy), a rare optic nerve condition that can cause sudden, painless vision loss in one eye, including permanent loss. Across 126 randomized trials (134,253 patients), NAION occurred 6.4 times per 100,000 person-years on GLP-1 drugs versus 3.8 on placebo or other diabetes drugs. FDA advises patients to contact a health care professional right away if they notice sudden vision loss in one eye, blind spots, color distortion or blurry spots, and says anyone who has had NAION should talk with their health care professional about whether to continue the medicine. (2026-11-09) source
Other notes
- Dulaglutide is one of the GLP-1 active ingredients covered by FDA Import Alert 66-80 (detention without physical examination of GLP-1 bulk drug substances from non-green-listed makers; revised September 2026). source
Checked October 28, 2026. Rules change; follow the source links for the current status. Regulatory tracker.
This is not a complete list of contraindications, interactions, or adverse effects. Medicine labels apply to specific products and indications; research-use listings are not interchangeable with approved medicines.
Approved uses in the United States
The March 2026 FDA label covers improved glucose control alongside diet and exercise in adults and children aged 10 and older with type 2 diabetes. It also covers reducing major cardiovascular events in adults with type 2 diabetes and established cardiovascular disease or multiple cardiovascular risk factors.
Weight management alone is not a listed indication. Approval belongs to the specified medicine and population; it does not extend to every product advertised with a peptide name.
Source: FDA · Trulicity prescribing information · March 2026 ↗
New editorial updates
New source discoveries
Links appear automatically. Unreviewed discoveries are not verified medical findings.
Sources & supplier listings
PepsRadar does not list, compare or link GLP-1-class products, even though some sellers we track elsewhere on the site also sell them. The approved medicine is available only with a prescription, through a pharmacy. The FDA warns that versions sold online as "research" products are unapproved and of unknown quality (FDA).
How dulaglutide works
Dulaglutide mimics an incretin signal. When blood glucose is elevated, it helps the pancreas release insulin; insulin allows tissues to take up glucose from the blood. It also slows stomach emptying and can reduce appetite. These actions connect its effects on glucose with the weight changes reported in some trials.
It is a diabetes-management medicine, not a cure. Medication, nutrition, activity, and monitoring remain parts of ongoing care. Its effects on blood sugar should be distinguished from evidence about clinical events such as heart attacks and strokes.
Molecular structure
Questions worth asking
- Which indication and formulation does the source describe?
- Does the video make a broader claim than the source supports?
- Evidence for a prescribed diabetes product is not evidence for an unverified research vial.
- What adverse effects, uncertainty, and conflicts of interest does the original source report?
Frequently asked questions
Does an improvement in HbA1c prove fewer heart attacks?
No. A laboratory outcome and a clinical event answer different questions. AWARD-11 examined glucose and weight; REWIND directly studied cardiovascular events. Read the endpoint before interpreting a headline.
Does “weight loss in a study” mean it is an obesity medicine?
No. The trial population and approved indication both matter. AWARD-11 observed weight changes in adults with diabetes taking metformin; that is not a study of treatment for obesity alone.
Have all dulaglutide studies been reviewed here?
No. This profile summarizes a current US label, patient information, and three selected trial abstracts. It is not a systematic review or an independently medically reviewed prescribing reference. Additional populations, comparisons, and longer-term follow-up may change the picture.
References & editorial record
- MedlinePlus · Dulaglutide ↗
- FDA · Trulicity prescribing information · March 2026 ↗
- REWIND · Gerstein et al. · The Lancet, 2019 ↗
- AWARD-11 · Frias et al. · Diabetes Care, 2021 ↗
- AWARD-PEDS · Arslanian et al. · NEJM, 2022 ↗
Source notes checked 2026-10-04. Original PepsRadar summaries. Not reviewed by a medical professional. Topic grouping is editorial navigation, not a treatment recommendation.
